Form 4: Cue Biopharma Executive Anish Suri Acquires 300,000 Stock Options

Anish Suri, President and CSO of Cue Biopharma, Inc., reported the acquisition of 300,000 stock options exercisable for common stock.

Summary

• Anish Suri, the President and CSO of Cue Biopharma, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 6, 2024, where Suri acquired 300,000 stock options.
• These options have an exercise price of $1.94.
• The options become exercisable in eight equal semi-annual installments starting on September 6, 2024.
• The options expire on March 5, 2034.
• Following the reported transaction, Suri directly owns 300,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options can be seen as a positive sign, but it's not necessarily indicative of significant positive news.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of stock options is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in the biotechnology industry, often used to align management's interests with those of shareholders.
• The vesting schedule of eight equal semi-annual installments is a fairly typical arrangement.
• Comparing the size of the grant to those of executives at comparable companies (e.g., similar market cap, stage of development) would provide further context on the significance of this grant.

Stakeholder Impact

• The acquisition of stock options by a key executive could positively influence shareholder sentiment, reflecting confidence in the company's prospects.

Key Dates